Biosig Technologies Inc logo

BSGM - Biosig Technologies Inc News Story

$3.49 0.1  1.7%

Last Trade - 21/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £79.7m
Enterprise Value £60.0m
Revenue £n/a
Position in Universe 5053rd / 6852

Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems

Wed 10th February, 2021 3:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210210:nGNX20jld9&default-theme=true


Westport, CT, Feb. 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.
(NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology
company commercializing an innovative signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it has entered into three new evaluation
agreements for the PURE EP™ System, its novel electrophysiology (EP) signal
acquisition and analysis technology.

New installations of the PURE EP™ System will now follow a shorter
assessment cycle of 90 days based on favorable data from installation
evaluations in 2020. As part of its evaluation agreements, the Company’s
clinical team provides on-site training and assists with data collection and
interpretation, and workflow customization to optimize the user experience for
every physician and EP lab staff member.

“Since initiating our first clinical study in November 2019, our team has
acquired a wealth of knowledge about the capabilities of the PURE EP™ System
in a broad range of clinical cases,” commented Kenneth L. Londoner,
Chairman, and CEO of BioSig Technologies, Inc. “Our experience in 2020 has
provided the Company meaningful strategic information that gives us confidence
in accelerating our rollout and reducing the clinical evaluation period to 90
days or less, beginning with these three major hospitals.  With the recent
decline of COVID-19 cases reported and the resulting decline in
hospitalization rates in the past several weeks, our Company is poised to
expand near-term activity on our targeted commercial plans for 2021.”

New clinical sites due to receive BioSig’s PURE EP™ System include New
York-Presbyterian/Weill Cornell Medical Center, Michigan Medicine–University
Hospital (two centers that account for two of the largest EP programs in the
country), and Houston Methodist Hospital.

More than 500 patient cases have been conducted using the PURE EP™ System
by 34 physicians in seven clinical sites to date.

About BioSig Technologies
 BioSig Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system
intended for acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of electrocardiographic and
intracardiac signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.

Forward-looking Statements 
This press release contains “forward-looking statements.” Such statements
may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or
similar words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to various known
and unknown risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) the geographic, social
and economic impact of COVID-19 on our ability to conduct our business and
raise capital in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own, or in
collaboration with third parties; (iii) difficulties in obtaining financing on
commercially reasonable terms; (iv) changes in the size and nature of our
competition; (v) loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products and
product candidates. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set
forth in the Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or otherwise. 



Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133



(https://www.globenewswire.com/NewsRoom/AttachmentNg/c173d8f8-007c-446f-a74c-dc4fc3ad1512)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.